Searched for
ASTRAZENECA CANCER DRUG
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weighLondon’s FTSE 100 edged lower as losses in energy majors and AstraZeneca weighed on the index amid thin holiday trading. Weak crude prices ...
- AstraZeneca gets regulator's nod to market cancer drug in IndiaAstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now appro...
- AstraZeneca breast cancer medicine slows disease by over six monthsAstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six months in tria...
- AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drugAstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and...
- Over 3k brands hit pharma mkt, cancer drug tops in salesIndia's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, ref...
- China detains AstraZeneca staff in data, drug-import probes: Report"We are aware a small number of our employees in China are under investigation and we have no further information to share at this point," ...
- AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fightOn Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $1...
- DCGI orders withdrawal of cancer drug Olaparib for certain treatmentsThe Drug Controller General of India has requested the withdrawal of AstraZeneca's Olaparib tablets for certain cancer treatments due to po...
- AstraZeneca to buy fusion for $2 billionThe deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when ...
- AstraZeneca targets 2024 growth but mixed views hit sharesIn almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...
- AstraZeneca gets CDSCO nod for drug to treat biliary tract cancerDrug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary trac...
- AstraZeneca India receives DCGI's nod to market drug treating breast cancerThe Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with ear...
- High Court rejects AstraZeneca’s diabetes drug pleaThe Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Ongly...
- Good cancer drug data helps AstraZeneca in Pfizer fightBritain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.
- AstraZeneca leaves door ajar to Pfizer, despite hurdlesAstraZeneca's boss said he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's ops int...
- Patents appeal board rejects AstraZeneca's plea on cancer drugPatents appeal board has dismissed AstraZeneca's petition challenging an earlier ruling that refused patent protection for a cancer-fightin...
Load More
